Search Results - "Casañ, V Arocas"

Experience with tocilizumab in patients with neuromyelitis optica spectrum disorders by Carreón Guarnizo, E., Hernández Clares, R., Castillo Triviño, T., Meca Lallana, V., Arocas Casañ, V., Iniesta Martínez, F., Olascoaga Urtaza, J., Meca Lallana, J.E.

“…Neuromyelitis optica spectrum disorders (NMOSD) are immune-mediated inflammatory disorders of the central nervous system involving astrocytes, B lymphocytes,…”
Get full text

Experience with tocilizumab in patients with neuromyelitis optica spectrum disorders by Carreón Guarnizo, E, Hernández Clares, R, Castillo Triviño, T, Meca Lallana, V, Arocas Casañ, V, Iniesta Martínez, F, Olascoaga Urtaza, J, Meca Lallana, J E

“…INTRODUCTIONNeuromyelitis optica spectrum disorders (NMOSD) are immune-mediated inflammatory disorders of the central nervous system involving astrocytes, B…”
Get full text

4CPS-106 Analysis of the prescription and safe drug administration of ocrelizumab by García Soler, JI, Arocas Casañ, V, Menendez Naranjo, L, Gonzalez Lozano, E, Laorden Carrasco, A, Diaz Ramon, M, Cano Molina, JA, Ramirez Roig, C, Valderrey Pulido, M, Vicente Sánchez, S

“…Background and importanceOcrelizumab is the first drug approved in Europe for the treatment of primary progressive multiple sclerosis (PPMS). It is an…”
Get full text

CP-175 Descriptive analysis of active clinical trials in cardiology service by Soler, JI García, de Vera, A Pareja Rodríguez, Casañ, V Arocas, Molina, OM García, Comendador, S Martínez, Lozano, E González, Luz, A Tomas, Jiménez, MDM Ruiz, Sánchez, S Vicente, De la Rubia Nieto, A

“…BackgroundCardiovascular diseases are the leading cause of death in Europe making it necessary to promote research projects.PurposeTo describe active…”
Get full text

CP-091 Analysis of off-label use of levosimendan in paediatrics by Carmona, J Mateo, Molina, O García, Casañ, V Arocas, Espinosa, MA Fernández De Palencia, Pulido, M Valderrey, Sánchez, S Vicente, Luiz, A Tomás, Jiménez, MM Ruiz, Murie, P De La Cruz, Rueda, M Galindo

“…BackgroundLevosimendan is a calcium sensitising inodilator agent that is indicated for the short term treatment of severe acute decompensation of chronic heart…”
Get full text

Experience with tocilizumab in patients with neuromyelitis optica spectrum disorders by Carreón Guarnizo, E, Hernández Clares, R, Castillo Triviño, T, Meca Lallana, V, Arocas Casañ, V, Iniesta Martínez, F, Olascoaga Urtaza, J, Meca Lallana, J E

“…Neuromyelitis optica spectrum disorders (NMOSD) are immune-mediated inflammatory disorders of the central nervous system involving astrocytes, B lymphocytes,…”
Get full text

Retrospective descriptive study about the use of levosimendan in children undergoing surgical correction for congenital heart disease by Fernández de Palencia-Espinosa, M A, Cárceles-Barón, M D, Blázquez-Álvarez, M J, Arocas-Casañ, V, de la Rubia-Nieto, A

“…To describe the use of levosimendan for compassionate use in children undergoing surgery for congenital heart disease, as well as survival rates, and the…”
Get more information

Experiencia con tocilizumab en pacientes con espectro de la neuromielitis óptica by Carreón Guarnizo, E., Hernández Clares, R., Castillo Triviño, T., Meca Lallana, V., Arocas Casañ, V., Iniesta Martínez, F., Olascoaga Urtaza, J., Meca Lallana, J.E.

“…El espectro de la neuromielitis óptica (ENMO) es una enfermedad inflamatoria del sistema nervioso central con patogenia inmunomediada que implica a astrocitos,…”
Get full text

Acquired haemophilia A in a patient with chronic hepatitis C virus infection receiving treatment with pegylated interferon plus ribarivin: role of rituximab by Fernández de Palencia Espinosa, M Á, Arocas Casañ, V, Garrido Corro, B, de la Rubia Nieto, A

“…Acquired haemophilia is an uncommon condition caused by the development of clotting factor inhibitors. To eliminate them, immunosuppressive therapy with…”
Get more information